Shearman & Sterling represented Morgan Stanley Senior Funding, Inc., Barclays Bank Plc, J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated as joint lead arrangers and joint bookrunners in connection with a $14.5 billion aggregate financing, including a $5 billion five-year revolving credit facility for Abbot Laboratories, a $2 billion five-year revolving credit facility for Abbott Laboratories and AbbVie Inc. and a $7.5 billion 364-day bridge guaranteed financing for AbbVie Inc. These financing transactions will be used, in part, in connection with transactions related to the spin-off of the research-based pharmaceuticals business of Abbott Laboratories.
The Shearman & Sterling team included partners Maura O’Sullivan (New York-Finance), Laurence Bambino (New York-Tax), Michael Benjamin(New York-Capital Markets); counsel Richard Alsop (New York-Capital Markets) and Susan L. Hobart (New York-Finance); and associates Alexander Heckscher (New York-Finance), Judson Oswald (New York-Finance), Derek Kershaw (New York-Tax) and Quentin Wiest (New York-Capital Markets).
